Your browser is no longer supported. Please, upgrade your browser.
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-2.47 Insider Own0.10% Shs Outstand51.70M Perf Week-3.30%
Market Cap1.55B Forward P/E- EPS next Y-2.92 Insider Trans-9.34% Shs Float50.24M Perf Month30.06%
Income-121.00M PEG- EPS next Q-0.07 Inst Own81.80% Short Float16.79% Perf Quarter16.12%
Sales14.40M P/S107.35 EPS this Y21.80% Inst Trans4.17% Short Ratio10.58 Perf Half Y32.24%
Book/sh4.21 P/B7.10 EPS next Y- ROA-31.70% Target Price46.71 Perf Year3.32%
Cash/sh6.43 P/C4.65 EPS next 5Y- ROE-56.50% 52W Range17.80 - 31.78 Perf YTD31.43%
Dividend- P/FCF- EPS past 5Y- ROI-42.30% 52W High-5.92% Beta2.64
Dividend %- Quick Ratio5.10 Sales past 5Y- Gross Margin- 52W Low67.98% ATR1.36
Employees133 Current Ratio5.10 Sales Q/Q-73.80% Oper. Margin- RSI (14)66.75 Volatility4.08% 5.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-105.70% Profit Margin- Rel Volume0.88 Prev Close30.13
ShortableYes LT Debt/Eq0.00 EarningsNov 12 BMO Payout- Avg Volume797.27K Price29.90
Recom- SMA207.82% SMA5026.74% SMA20024.36% Volume697,833 Change-0.76%
Apr-12-19Initiated Evercore ISI Outperform
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Outperform $40
May-15-18Reiterated Chardan Capital Markets Buy $72.50 → $55
Feb-13-18Initiated CLSA Underperform
Jan-23-18Upgrade SunTrust Hold → Buy
Jul-14-17Initiated SunTrust Hold $17
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
Dec-14-19 08:42PM  Did Hedge Funds Drop The Ball On Editas Medicine, Inc. (EDIT) ? Insider Monkey
Dec-12-19 11:30AM  Why Is Editas (EDIT) Up 28.7% Since Last Earnings Report? Zacks
Dec-09-19 06:00PM  Editas Medicine Announces In Vivo Proof-of-Concept Data for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
Dec-03-19 01:03AM  Don't Judge a Month by its First Day Zacks
Dec-02-19 11:43AM  Edited Transcript of EDIT earnings conference call or presentation 12-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-20-19 09:41AM  Editas Medicine (EDIT) in Focus: Stock Moves 7.8% Higher Zacks
09:12AM  Vertex, CRISPR's Gene Editing Drug Shows Positive Early Data Zacks
01:05AM  The NASDAQ Needs No Break Zacks
Nov-19-19 10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals +7.82%
Nov-13-19 10:00AM  Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal Zacks
Nov-12-19 08:35AM  Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates Zacks +9.47%
07:02AM  Editas Medicine Announces Third Quarter 2019 Results and Update GlobeNewswire
07:00AM  Editas Medicine and Celgene Corporation Amend Existing Collaboration to Develop and Commercialize Autologous and Allogeneic T Cell Medicines for the Treatment of Cancer and Autoimmune Diseases GlobeNewswire
Nov-05-19 08:00AM  Editas Medicine to Host Conference Call Discussing Third Quarter 2019 Results and Corporate Update GlobeNewswire
Oct-31-19 04:30AM  8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 11:10AM  Analysts Estimate Editas Medicine (EDIT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-19 04:05PM  Experts Talk Hot Biotech Stocks at Barrons Breakfast Barrons.com
Oct-28-19 06:55PM  Editas Medicine Appoints Judith R. Abrams, M.D., as Chief Medical Officer GlobeNewswire
12:10PM  Is Editas Medicine, Inc. (EDIT) Going to Burn These Hedge Funds? Insider Monkey
Oct-23-19 10:32AM  Moving Average Crossover Alert: Editas Medicine Zacks
Oct-19-19 10:29AM  Companies Like Editas Medicine (NASDAQ:EDIT) Are In A Position To Invest In Growth Simply Wall St.
Oct-16-19 12:16PM  Editas Inks Deal for Gene Editing Neurological Disease Drugs Zacks
10:13AM  CRISPR Therapeutics Enters New License Agreement, Shares Up Zacks
Oct-15-19 06:15PM  Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases GlobeNewswire
Oct-07-19 07:00AM  Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines GlobeNewswire
Oct-01-19 08:00AM  Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-13-19 10:06AM  Adverum Reports Data From Phase I Wet AMD Study, Stock Down Zacks
Sep-06-19 03:07PM  ETFs Poised to Benefit from Gene Editing Revolution Zacks
Sep-05-19 09:31AM  Why Is Editas (EDIT) Down 5.5% Since Last Earnings Report? Zacks
09:15AM  How Boulder biotech companies are putting Colorado on the gene-editing map American City Business Journals
Sep-04-19 12:52PM  Need To Know: Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Have Been Buying Shares Simply Wall St.
Aug-29-19 08:00AM  Editas Medicine to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-27-19 09:10AM  CRISPR gene-editing technique set to push new boundaries MarketWatch
Aug-13-19 08:27PM  Edited Transcript of EDIT earnings conference call or presentation 6-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-12-19 04:05PM  Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors GlobeNewswire
Aug-08-19 10:09AM  Bayer buys Cambridge cell therapy startup BlueRock at $1B value American City Business Journals
09:50AM  Editas Medicine, Inc. (EDIT) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 09:32AM  Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO Zacks
Aug-06-19 09:10PM  Editas Medicine Remains on Track Motley Fool
06:05PM  Editas Medicine (EDIT) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:15PM  Editas Medicine Announces Second Quarter 2019 Results and Update GlobeNewswire
Aug-01-19 06:16AM  Legal fight over Broad Institute's patent for CRISPR gene editing flares up again American City Business Journals
Jul-31-19 12:41PM  Is Intellia Therapeutics a Buy? Motley Fool -5.82%
Jul-30-19 04:02PM  Editas Medicine to Host Conference Call Discussing Second Quarter 2019 Results and Corporate Update GlobeNewswire
Jul-29-19 10:34AM  Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-25-19 09:00AM  Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN-151587 (EDIT-101) for the Treatment of LCA10 GlobeNewswire
Jul-23-19 04:44PM  CRISPR Could Change Medicine, But Not in the Way Wall Street Expects Motley Fool
Jul-10-19 08:16AM  Here's Why CRISPR Gene Editing Stocks Rose as Much as 32.4% in June Motley Fool
Jul-07-19 07:32AM  Is Editas Medicine a Buy? Motley Fool
Jul-05-19 08:57AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
Jul-04-19 12:47PM  What Kind Of Shareholders Own Editas Medicine, Inc. (NASDAQ:EDIT)? Simply Wall St.
Jul-01-19 11:12PM  How to Invest in Biotech Stocks Motley Fool
09:15AM  Stocks Soar 7% in June Zacks
Jun-25-19 10:19AM  Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy? Insider Monkey
Jun-15-19 11:30AM  Editas Medicine Presents Pre-Clinical Data for Treatment of Sickle Cell Disease and Beta-Thalassemia at the 24th Congress of the European Hematology Association GlobeNewswire
Jun-14-19 09:00AM  Glaxo Inks Genome Research Deal With University of California Zacks
Jun-11-19 06:00AM  Is the Newest Gene Editing Stock a Buy? Motley Fool
Jun-10-19 09:29AM  CRISPR Therapeutics Up on Collaboration Expansion by Vertex Zacks
Jun-07-19 07:45AM  Why I'm Sticking With My 3 Worst-Performing Stocks of 2019 So Far Motley Fool +8.89%
Jun-06-19 09:17AM  Life sciences VC firm Third Rock raises $770M in its largest round ever American City Business Journals
May-20-19 04:14PM  Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study Zacks
May-19-19 10:58PM  Edited Transcript of EDIT earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-17-19 06:00AM  3 Small-Cap Biotech Stocks You Can Buy Right Now Motley Fool
May-10-19 10:11AM  Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil Zacks
May-09-19 03:03PM  IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus Zacks
May-08-19 05:28PM  Editas Gears Up for a Busy 2019 Motley Fool
12:23AM  Editas Medicine, Inc. (EDIT) Q1 2019 Earnings Call Transcript Motley Fool
May-07-19 06:05PM  Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:57PM  Editas: 1Q Earnings Snapshot Associated Press
04:01PM  Editas Medicine Announces First Quarter 2019 Results and Update GlobeNewswire
06:01AM  After $59M round, CRISPR startup launches with plans to tackle heart disease American City Business Journals
May-06-19 09:58AM  Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up Zacks
09:44AM  ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1 Zacks
May-03-19 03:40PM  Did Changing Sentiment Drive Editas Medicine's (NASDAQ:EDIT) Share Price Down By 27%? Simply Wall St.
09:30AM  Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? Zacks
09:24AM  Here is What Hedge Funds Think About Editas Medicine, Inc. (EDIT) Insider Monkey
May-02-19 04:26PM  Is Editas Medicine, Inc. (EDIT) A Good Stock To Buy? Insider Monkey
Apr-30-19 04:01PM  Editas Medicine to Host Conference Call Discussing First Quarter 2019 Results and Corporate Update GlobeNewswire -5.79%
Apr-29-19 09:19AM  Allergan and Editas Medicine Announce Initial Data from Natural History Study to Evaluate Patients with Leber Congenital Amaurosis 10 (LCA10) GlobeNewswire -5.37%
Apr-27-19 01:00PM  Better Buy: Editas Medicine vs. CRISPR Therapeutics Motley Fool
Apr-25-19 11:15AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
10:34AM  Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward GuruFocus.com -5.51%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:39PM  Bain Capital raising another life sciences fund after $720M debut American City Business Journals
Apr-10-19 02:00PM  3 Top Small-Cap Stocks to Buy in April Motley Fool
Apr-09-19 03:33PM  These Cannabis and China ETFs are Leading the 2019 Rally Investopedia
10:33AM  How Editas Medicine Could Make You Better (and Richer) Motley Fool
09:53AM  5 Stocks in the Age of Miracles Motley Fool
Apr-07-19 02:00PM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Apr-04-19 03:39PM  Editas (EDIT) Inks Cross Licensing Agreement with BlueRock Zacks
10:33AM  Why Editas Medicine Stock Popped 18.5% in March Motley Fool
Apr-03-19 04:11PM  CRISPR Biotech Inks Deal To Use Stem Cells In Gene-Editing Medicine Investor's Business Daily
09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
07:00AM  Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms GlobeNewswire
Mar-26-19 07:16AM  Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool
07:10AM  Research Report Identifies Spirit Airlines, Integrated Device Technology, Editas Medicine, MACOM Technology Solutions, Taylor Morrison Home, and Brunswick with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace
Mar-18-19 12:38PM  What Do Investors Need To Know About Editas Medicine, Inc.s (NASDAQ:EDIT) Earnings Outlook? Simply Wall St.
Mar-12-19 06:00AM  3 Stocks That Could Double Your Money Motley Fool
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company also has a strategic research collaboration agreement with Editas Medicine, Inc. to explore in vivo delivery of genome editing medicines to treat neurological diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Collins CynthiaCEOAug 19Sale25.835,193134,13511,373Aug 21 04:03 PM
Myer VickeshChief Technology OfficerMar 18Option Exercise0.653,0001,9503,000Mar 20 04:02 PM
Myer VickeshChief Technology OfficerMar 18Sale24.503,00073,5000Mar 20 04:02 PM
Hopfield JessicaDirectorMar 05Buy23.9410,200244,18816,900Mar 07 04:02 PM
Myer VickeshChief Technology OfficerFeb 20Option Exercise0.653,0001,9503,000Feb 22 04:11 PM
Myer VickeshChief Technology OfficerFeb 20Sale20.423,00061,2600Feb 22 04:11 PM
Hack Andrew A. F.Chief Financial OfficerFeb 04Option Exercise6.486,89544,6806,895Feb 06 04:41 PM
Hack Andrew A. F.Chief Financial OfficerFeb 04Sale21.396,895147,4840Feb 06 04:41 PM
Myer VickeshChief Technology OfficerJan 18Option Exercise11.214,00044,8404,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 18Sale26.504,000106,0000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Option Exercise0.653,0001,9503,000Jan 18 08:58 PM
Myer VickeshChief Technology OfficerJan 17Sale26.183,00078,5400Jan 18 08:58 PM
Bosley KatrinePresident and CEOJan 08Sale25.2712,000303,2401,204,966Jan 10 04:11 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Option Exercise6.487,00045,3607,000Jan 08 05:36 PM
Hack Andrew A. F.Chief Financial OfficerJan 04Sale22.487,000157,3600Jan 08 05:36 PM
Myer VickeshChief Technology OfficerDec 18Option Exercise11.214,00044,8404,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 18Sale27.414,000109,6400Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Option Exercise0.653,0001,9503,000Dec 19 04:41 PM
Myer VickeshChief Technology OfficerDec 17Sale27.893,00083,6630Dec 19 04:41 PM